<DOC>
	<DOCNO>NCT01642966</DOCNO>
	<brief_summary>This prospective , randomize , single-blind , investigator-initiated , crossover study . Patients Acute Coronary Syndrome ( ACS ) subject percutaneous coronary intervention ( PCI ) , randomize informed consent , 1:1 ratio either ticagrelor 90mg x2 prasugrel 10mg x1 15 day . At Day 15± 2 day , coronary diastolic blood flow velocity leave anterior descend artery ( LAD ) evaluate baseline ( bCBFV ) 2 min adenosine infusion ( maximal diastolic CBFV- maxCBFV ) gradually increase dos 50μg/kg/min , 80μg/kg/min , 110μg/kg/min 140μg/kg/min least 5 min recovery interval infusion . A crossover directly alternate treatment perform followed evaluation Day 30±2 day .</brief_summary>
	<brief_title>Differential Effect Ticagrelor Versus Prasugrel Adenosine-induced Coronary Vasodilatory Responses Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Age 1874 year Patients acute coronary syndrome undergo PCI stenting Sinus rhythm Written inform consent Known hypersensitivity prasugrel ticagrelor Requirement oral anticoagulant prior Day 30 visit Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) Any active bleeding history gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 3 month , bleed diathesis , consider investigator high risk bleed Concomitant oral IV therapy strong CY P3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazana vir , grapefruit juice N1 L/d ) , CYP3A substrates narrow therapeutic index ( cyclosporine , quinidine ) , strong CYP3A inducer ( rifampin /rifampicin , phenytoin , carbamazepine ) . Increased risk bradycardiac event . Dialysis require . Severe uncontrolled chronic obstructive pulmonary disease Known severe hepatic impairment Pregnancy breastfeeding Left ventricular ejection fraction &lt; 45 % , severe leave ventricular hypertrophy , diastolic dysfunction , severe valve disease Prior myocardial infarction , percutaneous coronary intervention coronary artery bypass graft Weight &lt; 60 Kg Alcohol narcotic abuse Major periprocedural complication : death , cardiogenic shock , stent thrombosis , arrhythmia require cardioversion/defibrillation , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , retroperitoneal bleeding , major bleeding ( need blood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) , unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) plan stag PCI next 5 day randomization Any residual stenosis &gt; 40 % LAD Small vessel diffuse coronary atherosclerosis Inability detect coronary blood flow LAD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>doppler echocardiography</keyword>
</DOC>